R&D Innovations
By right of the international R&D system, widespread network resources, strong R&D competencies of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, coupled with its own R&D-clinical-application team and sufficient experience in IND, NDA and ANDA, Avanc Pharma is able to meet the need for product innovation and development and inject vitality and competitive strength to the Company for fast, stable and sustainable growth.
R&D and Innovation
R&D and Innovation
Innovation-driven Business Development
Avanc Pharma is committed to innovation-driven business development and is exploring deeper into the nervous system, oncology, perioperative drugs and pediatric drugs. In addition to 37 granted patents, the Company has 30-plus new drugs in the pipeline, including three new drugs of class 1.1, all supported by the “National New Drug Innovation Program”. While importing generic drugs with a high-tech barrier, the Company stays focused on pediatric drugs targeting common and uncommon diseases seen in children and new formulations ideal for pediatric medication, and makes continued efforts to expand its R&D pipelines and build a core competive edge of its products.
R&D Pipelines
China Invention Patents
International R&D System
International R&D System
Global Integration of R&D
Avanc Pharma has built a team capable of original innovations, while continuously optimizing the “generic+patented” drug R&D system. It has deployed a globally coordinated R&D network by bringing in new drugs invented at home and abroad and integrating quality pharmaceutical companies.
International BD and international joint R&D partners in——
USA Japan India Denmark Portugal Italy Uzbekistan……
R&D Innovations
By right of the international R&D system, widespread network resources, strong R&D competencies of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, coupled with its own R&D-clinical-application team and sufficient experience in IND, NDA and ANDA, Avanc Pharma is able to meet the need for product innovation and development and inject vitality and competitive strength to the Company for fast, stable and sustainable growth.
Innovation-driven
Business Development
Avanc Pharma is committed to innovation-driven business development and is exploring deeper into the nervous system, oncology, perioperative drugs and pediatric drugs. In addition to 37 granted patents, the Company has 30-plus new drugs in the pipeline, including three new drugs of class 1.1, all supported by the “National New Drug Innovation Program”. While importing generic drugs with a high-tech barrier, the Company stays focused on pediatric drugs targeting common and uncommon diseases seen in children and new formulations ideal for pediatric medication, and makes continued efforts to expand its R&D pipelines and build a core competive edge of its products.
R&D pipelines：32
China Invention Patents：37
Global Integration of R&D
Avanc Pharma has built a team capable of original innovations, while continuously optimizing the “generic+patented” drug R&D system. It has deployed a globally coordinated R&D network by bringing in new drugs invented at home and abroad and integrating quality pharmaceutical companies and CRO companies.
International BD and international joint R&D partners in:
USA, Japan, India, Denmark, Portugal, Italy, Uzbekistan……